Key TakeawaysNovavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.Regulators stopped testing last month as one patient had a serious adverse event after taking the shot.The company said further information supported its contention that the vaccine did not cause the problem, and it will now move to resume its research as soon as possible. Novavax (NVAX) shares edged higher Monday after the drugmaker announ ...

Novavax (NVAX) is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported quarter, the company’s earnings missed estimates by 45.60%.The Zacks Consensus Estimate for sales is pegged at $57.3 million while that for earnings is pinned at a loss of 87 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Factors Shaping NVAX’s Upcoming ResultsAlthough Novavax secured the FDA’s authorization for an updated version of its protei ...

Core Points - Novavax, Inc. has received clearance from the U.S. FDA to proceed with its Phase 3 trial for the COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates after addressing all clinical hold issues [1][2] - The clinical hold was initially imposed due to a serious adverse event reported during a Phase 2 trial, which was later determined to be unrelated to the vaccine [2] Company Overview - Novavax, Inc. is focused on developing innovative vaccines to combat serious infectious diseases, utilizing a recombinant protein approach and its patented Matrix-M adjuvant to enhance immune response [3] - The company's portfolio includes a COVID-19 vaccine and candidates for the CIC and stand-alone influenza vaccines, with its adjuvant also being used in other vaccine collaborations [3]

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on November 12, 2024, might help the stock move higher if these key numbers are ...

GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3Y6irHG Dia ...

Novavax (NVAX) closed the latest trading day at $10.07, indicating a -1.76% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq gained 0.78%. Shares of the vaccine maker have depreciated by 18.84% over the course of the past month, underperforming the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67%. Investors will be eagerly watching for the performance of Nov ...

Knowing these will help you avoid making suboptimal investing decisions. Once you're attuned to the ebbs and flows of the healthcare sector, there are a few dead ringers that'll send a chill up your spine in anticipation of your investments losing value, and soon. In keeping with the Halloween spirit, investors should thus be on the lookout for these three spooky signs that foretell a looming downturn in their healthcare stocks. 1. You invested right after a period of windfall profits or event-driven growth ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NVAX. Investigation Details On October 16, 2024, Novavax issued a press release “announc[ing] that the U.S. Food and Drug Adminis ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this vaccine maker have returned -21.2% over the past month versus the Zacks S&P 500 composite's +4.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax belongs, has lost 1.5% over this period. Now the key question is: Where could the stock be headed in the near term?While media ...

Let's look beyond this piece of bad news from regulators.Vaccine maker Novavax (NVAX -1.64%) has had a rollercoaster of a year. In May, the company's shares soared after it announced a lucrative agreement with biotech giant Sanofi. It's been mostly downhill for Novavax since then, though that's likely due to some profit taking by investors.However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock price is still up by more than 100% for the ...